Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
![](https://catedrasaludrespiratoria.com/wp-content/uploads/2024/03/athsma-y-COPD.jpg)
Bronchodilator Responsiveness (BDR) prevalence in patients with chronic airway diseases receiving treatment ranges from 18% to 30%, being modestly lower with the 2021 than with the 2005 European Respiratory Society/American Thoracic Society criteria, and it is associated with lower lung function and greater symptom burden.
These observations question the validity of BDR as a key diagnostic tool for asthma managed in clinical practice or as a standard inclusion criterion for clinical trials of asthma and instead suggest that BDR be considered a treatable trait for chronic airway disease.
Measurements and Main Results
3,519 patients were studied with a physician-assigned diagnosis of asthma, 833 with a diagnosis of asthma + COPD, and 2,436 with a diagnosis of COPD.
The prevalence of BDR was 19.7% (asthma), 29.6% (asthma + COPD), and 24.7% (COPD) using 2005 criteria and 18.1%, 23.3%, and 18.0%, respectively, using 2021 criteria.
Using 2021 criteria in patients diagnosed with asthma, BDR was associated with higher fractional exhaled nitric oxide; lower lung function; higher symptom burden; more frequent hospital admissions; and greater use of triple therapy, oral corticosteroids, or biologics. In patients diagnosed with COPD, BDR (2021) was associated with lower lung function and higher symptom burden.
Puedes leer el artículo completo aquí: https://pubmed.ncbi.nlm.nih.gov/38029294/
Autores: Richard Beasley, Rod Hughes, Alvar Agusti, Peter Calverley, Bradley Chipps, Ricardo Del Olmo, Alberto Papi, David Price, Helen Reddel, Hana Müllerová, Eleni Rapsomaniki.
Noticias relacionadas
![DNA Methylation in COPD](https://catedrasaludrespiratoria.com/wp-content/uploads/2024/07/dna-methylation-in-copd-v2-300x225.webp)
Is the association between the severity of airflow limitation and DNA Methylation similar in blood and lung tissue in patients with COPD?
The relationship between airflow limitation severity and DNA methylation in COPD patients. Findings reveal CpGs with opposite associations in blood and lung tissues, highlighting distinct regulatory mechanisms.
![Treatable traits in pre-COPD](https://catedrasaludrespiratoria.com/wp-content/uploads/2024/07/Treatable-traits-in-pre-COPD-300x225.webp)
Treatable traits in pre-COPD: Time to extend the treatable traits paradigm beyond established disease
Explore how the treatable traits approach can be applied to pre-COPD, potentially preventing full disease development. Learn about GETomics and its role in understanding pre-COPD through gene-environment interactions.
![Epigenetic Age Acceleration in COPD Blood vs. Lung Tissue](https://catedrasaludrespiratoria.com/wp-content/uploads/2024/07/Epigenetic-Age-Acceleration-in-COPD-Blood-vs-Lung-Tissue-300x225.webp)
Epigenetic age acceleration and severity of airflow limitation on blood and lung tissue of COPD
Discover the distinct patterns of epigenetic age acceleration in COPD patients. Our study reveals significant associations between airflow limitation severity and biological age in blood, highlighting different aging biomarkers in lung tissue.
![Telemedicia y EPOC](https://catedrasaludrespiratoria.com/wp-content/uploads/2024/06/telemedicina-y-epoc-2-300x225.webp)
Uso limitado y posibles obstáculos para la implementación de herramientas de telemedicina para el manejo remoto de pacientes con EPOC entre los miembros de la SEPAR
La TM (telemedicina) podría ayudar en el tratamiento de la EPOC, pero aún queda un largo camino para poder implantar un sistema seguro a nivel nacional.
![](https://catedrasaludrespiratoria.com/wp-content/uploads/2024/02/pacientes-epoc-300x225.jpg)
From treatable traits to GETomics in airway disease: moving towards clinical practice
The treatable traits approach represents a strategy for patient management. It is based on the identification of characteristics susceptible to treatments or predictive of treatment response in each individual patient.
![](https://catedrasaludrespiratoria.com/wp-content/uploads/2023/12/primer-encuentro-anual-de-chiesi-patienttalks-1opt-300x225.webp)
Resumen del Primer Encuentro Anual de Pacientes de Chiesi – Chiesi PatientTalks
Primer Encuentro Anual de Pacientes de Chiesi: punto de encuentro de referencia y foro de debate y discusión para pacientes, profesionales sanitarios, así como otros agentes del sector salud, con el fin de ayudar a visibilizar sus necesidades.
Artículos
COPD
- 759578·Alberto Papi et Al.-Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
Imagen obtenida en artículo origninal.